Patient Deaths Stop Infinity Pharma's Phase III HSP90 Trial In Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Infinity Pharmaceuticals' decision to pull the plug on the registrational Phase III trial with heat shock protein 90 inhibitor IPI-504 - the only product not part of the broad-ranging deal with affiliated specialty pharmas Purdue and Mundipharma - put a chill into investors April 15